On January 2, 2019 Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, reported that CEO Stéphane Bancel will present an update on the Company and its pipeline of mRNA development programs at this year’s 37th annual J.P. Morgan Healthcare Conference (Press release, Moderna Therapeutics, JAN 2, 2019, View Source [SID1234532368]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mr. Bancel’s presentation will take place on Tuesday, January 8, 2019 at 10:30 a.m. PT in the Colonial Room at The Westin St. Francis Hotel in San Francisco. The presentation will be followed by a question and answer session. A live webcast of both the presentation and question and answer session can be accessed on the investors section of Moderna’s website at investors.modernatx.com. A replay of the webcast also will be archived on Moderna’s website for up to 30 days following the presentation.